Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Calcium Channel Blockers: Their Pharmacologic and Therapeutic Role in Hypertension

Calcium Channel Blockers: Their Pharmacologic and Therapeutic Role in Hypertension The prevalence of hypertension is increasing steadily in the US, particularly among African Americans. It is now clear that a large proportion of patients are inadequately controlled, with many patients requiring at least two agents to achieve their target BP. Calcium channel blockers (CCBs), comprising two subclasses — dihydropyridines and non-dihydropyridines — have been for many years one of the mainstays of hypertension therapy. However, the use of CCBs as monotherapy has recently been overshadowed by the introduction of newer classes of agents such as angiotensin receptor blockers. Examining the pharmacologic and clinical effects of CCBs in essential hypertension and among specific patient groups (e.g. African Americans, patients with renal disease) paves the way for understanding why these agents are currently enjoying a resurgence in popularity as the basis for several fixed-dose combination regimens that promise to improve BP control and reduce the risk of cardiovascular events. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Calcium Channel Blockers: Their Pharmacologic and Therapeutic Role in Hypertension

Loading next page...
 
/lp/springer-journals/calcium-channel-blockers-their-pharmacologic-and-therapeutic-role-in-gxUXEeybxc

References (128)

Publisher
Springer Journals
Copyright
Copyright © 2007 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200707001-00002
pmid
19847947
Publisher site
See Article on Publisher Site

Abstract

The prevalence of hypertension is increasing steadily in the US, particularly among African Americans. It is now clear that a large proportion of patients are inadequately controlled, with many patients requiring at least two agents to achieve their target BP. Calcium channel blockers (CCBs), comprising two subclasses — dihydropyridines and non-dihydropyridines — have been for many years one of the mainstays of hypertension therapy. However, the use of CCBs as monotherapy has recently been overshadowed by the introduction of newer classes of agents such as angiotensin receptor blockers. Examining the pharmacologic and clinical effects of CCBs in essential hypertension and among specific patient groups (e.g. African Americans, patients with renal disease) paves the way for understanding why these agents are currently enjoying a resurgence in popularity as the basis for several fixed-dose combination regimens that promise to improve BP control and reduce the risk of cardiovascular events.

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Dec 9, 2014

There are no references for this article.